Skip to main content

Table 1 Comparison of the characteristics of research units between prostate cancer and control groups

From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer

Characteristics Prostate Cancer (67) Control (40) P OR (95% CI)
Age (Year) 52.7 ± 12.2 55.6 ± 9.9 0.19 0.95 (0.9–1.02)
HPV positive samples Presence 31.3% (n = 21) 15% (n = 6) 0.060 1.84 (0.08–0.6)
EBV positive samples Presence 49.3% (n = 33) 40% (n = 16) 0.353 1.06 (0.8–1.39)
Mono HPV-infection 16.4% (11) 7.5% (n = 3) 0.289 1.06 (0.26–6.5)
Co-infection (EBV&HPV) 14.9% (n = 10) 7.5% (n = 3) 0.314 2.9 (0.18–45.2)
Mono EBV-infection 34.3% (n = 23) 42.5% (n = 17) 0.48 0.58 (0.17–2.6)
Non-EBV and Non-HPV samples 34.3% (n = 23) 42.5% (n = 17) 0.48 NA
HPV Genotype 6 4.8% (1/21) 0 0.248 1.23 (0.51–4.42)
11 0 16.7% (1/6)
16 47.6% (10/21) 50% (3/6)
18 33.3% (7/21) 33.33% (2/6)
33 3 (15.8%) 0
EBV Genotype 1 9.09% (3/33) 0 0.105 0.55 (0.077–3.71)
2 90.9% (30/33) 100% (20/20)
Type of Cancer Acinar adenocarcinoma 40 (59.7%) NA NA
Ductal Adenocarcinoma 21 (31.34%) NA NA
Squamous cell cancer 6 (8.95%) NA NA
Stage of Cancer I 4 (5.9%) NA NA
IIA 9 (13.4%) NA NA
IIB 9 (13.4%) NA NA
IIC 5 (7.4%) NA NA
IIIA 2 (2.98%) NA NA
IIIB 10 (14.9%) NA NA
IIIC 6 (8.9%) NA NA
IVA 12 (17.9%) NA NA
IVB 10 (14.9%) NA NA
  1. NA Not applicable